JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

The data readout from the mid-stage DME study demonstrated that treatment with the candidate resulted in vision gains, non-inferior to Regeneron’s Eylea, at weeks 24 and 36 in the difficult-to ...

Seigerman views the recent court decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth potential. He is particularly ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...